4DX signs agreements with national lung screening sites
| Stock | 4DMEDICAL Ltd (4DX.ASX) |
|---|---|
| Release Time | 8 Sep 2025, 8:38 a.m. |
| Price Sensitive | Yes |
4DX signs agreements with national lung screening sites
- Collaboration with leading global pharmaceutical company to launch lung health screening program in Brazil
- Royal Melbourne Hospital to pilot 4DMedical's full portfolio for advanced lung ventilation analysis and clinical imaging assessment
- 4DMedical and Spectrum Medical Imaging enter multi-year agreement to support National Lung Cancer Screening Program in Australia
4DMedical Limited, a global leader in respiratory imaging technology, has announced agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software. The agreements, spanning to 2027, aim to support lung cancer screening, including the recently commenced National Lung Cancer Screening Program (NLCSP) in Australia, and improve lung health assessment. Under the agreement with the global pharmaceutical company, 4DMedical has commenced the rollout of a Lung Health Screening program in Brazil, focusing on lung cancer screening and the detection of incidental findings such as coronary artery calcification and chronic obstructive pulmonary disease. Royal Melbourne Hospital has entered into a pilot agreement to deploy the full 4DMedical portfolio to support advanced lung ventilation analysis and clinical imaging assessment of lung health. This includes CT LVAS, XV LVAS, LDAi, LDAf, Lung Texture Analysis, and low-dose CT nodule detection as part of the NLCSP. 4DMedical has also entered into a multi-year agreement with Spectrum Medical Imaging (NSW) to support its Lung Health programs, including low-dose CT nodule detection in the NLCSP. The agreement broadens the technology stack to include low-dose CT nodule detection and the structural suite of CT reports.
4DMedical is committed to Australian healthcare and is excited to support the National Lung Cancer Screening Program, believing its suite of products can play a big role. The company is also pleased to see progress on other products in the portfolio in countries where CT:VQ is yet to receive regulatory clearance, and looks forward to providing shareholders with further updates.